Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

631 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial.
Ogutu B, Yeka A, Kusemererwa S, Thompson R, Tinto H, Toure AO, Uthaisin C, Verma A, Kibuuka A, Lingani M, Lourenço C, Mombo-Ngoma G, Nduba V, N'Guessan TL, Nassa GJW, Nyantaro M, Tina LO, Singh PK, El Gaaloul M, Marrast AC, Chikoto H, Csermak K, Demin I, Mehta D, Pathan R, Risterucci C, Su G, Winnips C, Kaguthi G, Fofana B, Grobusch MP. Ogutu B, et al. Among authors: grobusch mp. Lancet Infect Dis. 2023 Sep;23(9):1051-1061. doi: 10.1016/S1473-3099(23)00209-8. Epub 2023 Jun 13. Lancet Infect Dis. 2023. PMID: 37327809 Clinical Trial.
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial.
Zinsou JF, Diemert DJ, Dejon-Agobé JC, Adégbité BR, Honkpehedji YJ, Vodonou KG, Bikangui R, Edoa JR, Massinga Loembe M, Li G, Yazdanbakhsh M, Bottazzi ME, van Leeuwen R, Kremsner PG, Hotez PJ, Bethony JM, Grobusch MP, Adegnika AA. Zinsou JF, et al. Among authors: grobusch mp. Lancet Infect Dis. 2024 Jul;24(7):760-774. doi: 10.1016/S1473-3099(24)00104-X. Epub 2024 Mar 18. Lancet Infect Dis. 2024. PMID: 38513684 Clinical Trial.
Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study.
Sangana R, Ogutu B, Yeka A, Kusemererwa S, Tinto H, Toure AO, Kibuuka A, Lingani M, Lourenço C, Mombo-Ngoma G, Nduba V, Landry N'Guessan T, Nassa GJW, Nyantaro M, Tina LO, Anvikar A, Sinha A, Kaguthi G, Fofana B, Grobusch MP, Gaaloul ME, Marrast AC, Pathan R, Chikoto H, Csermak K, Risterucci C, Su G, Winnips C, Zhang J, Zack J. Sangana R, et al. Among authors: grobusch mp. J Clin Pharmacol. 2024 Sep 29. doi: 10.1002/jcph.6138. Online ahead of print. J Clin Pharmacol. 2024. PMID: 39344281
Consensus definitions in imported human schistosomiasis: a GeoSentinel and TropNet Delphi study.
Tamarozzi F, Mazzi C, Antinori S, Arsuaga M, Becker SL, Bottieau E, Camprubi-Ferrer D, Caumes E, Duvignaud A, Grobusch MP, Jaureguiberry S, Jordan S, Mueller A, Neumayr A, Perez-Molina JA, Salas-Coronas J, Salvador F, Tomasoni LR, van Hellemond JJ, Vaughan SD, Wammes LJ, Zammarchi L, Buonfrate D, Huits R, van Lieshout L, Gobbi F. Tamarozzi F, et al. Among authors: grobusch mp. Lancet Infect Dis. 2024 Oct;24(10):e627-e637. doi: 10.1016/S1473-3099(24)00080-X. Epub 2024 Mar 8. Lancet Infect Dis. 2024. PMID: 38467128 Review.
On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives.
Schnyder JL, de Jong HK, Bache EB, van Hest RM, Schlagenhauf P, Borrmann S, Hanscheid T, Grobusch MP. Schnyder JL, et al. Among authors: grobusch mp. Travel Med Infect Dis. 2023 Mar-Apr;52:102520. doi: 10.1016/j.tmaid.2022.102520. Epub 2022 Dec 14. Travel Med Infect Dis. 2023. PMID: 36526126 Free article.
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Domínguez J, et al. Among authors: grobusch mp. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28. Lancet Infect Dis. 2023. PMID: 36868253 Free PMC article. Review.
631 results